We show that ECFCs from patients with T1D show exacerbated increases in mRNA levels of pro‐atherogenic/pro‐inflammatory genes (IL6 and CCL2) with IL‐1β treatment and reduced induction of the interferon marker (CXCL10) with TNFɑ compared to ECFCs from healthy donors. This evidence concerns the gene CXCL10 and type 1 diabetes mellitus.